Beginning Cash: The amount of cash reported by the company on its previous statement.
Crescent Biopharma, Inc. (CBIO) had Beginning Cash of $34.77M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-21.79M |
|
-- |
|
-- |
|
$21.03M |
|
$-21.03M |
|
$-0.76M |
|
$-21.79M |
|
$-21.79M |
|
$-21.79M |
|
$-21.79M |
|
$-21.79M |
|
$-21.79M |
|
$-21.03M |
|
$-21.03M |
|
3.86M |
|
3.86M |
|
$-4.93 |
|
$-4.93 |
|
| Balance Sheet Financials | |
$154.23M |
|
$0.19M |
|
$3.21M |
|
$157.43M |
|
$16.75M |
|
-- |
|
$1.43M |
|
$18.18M |
|
$135.25M |
|
$139.25M |
|
$139.25M |
|
13.89M |
|
| Cash Flow Statement Financials | |
$-27.25M |
|
$-0.14M |
|
$145.38M |
|
|
Beginning Cash |
$34.77M |
$152.75M |
|
$117.98M |
|
$6.57M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
9.21 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-27.39M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-16.11% |
|
-15.65% |
|
-13.84% |
|
-15.65% |
|
$10.02 |
|
$-7.10 |
|
$-7.07 |
|